Meningitis B Vaccine Eligibility Broadened in Kent as Cases Increase
Health Secretary Wes Streeting has announced an expansion of the meningitis B vaccine rollout in Kent, targeting more individuals affected by a recent outbreak. The decision was confirmed during a visit to the University of Kent on Thursday, 19 March 2026, as health officials work to contain the spread of the disease.
Updated Eligibility Criteria for Vaccination
The vaccine will now be offered to a wider group, including anyone who attended Club Chemistry from 5 March until its closure. These individuals are urged to come forward for both the vaccine and prophylactic antibiotics. Additionally, the expansion covers students at the University of Kent and some at Canterbury Christchurch University who were previously offered antibiotics, as well as sixth form pupils at four schools with known or suspected cases. The University of Kent has opened a clinic in its sports centre, making all students and staff eligible.
Current Vaccination Statistics and Future Plans
According to Mr. Streeting, over 600 vaccinations were administered on the first afternoon of the rollout, with thousands more students expected to receive the jab in the coming days. While there are no immediate plans for a nationwide catch-up programme, 40 MPs have signed a letter calling for collaboration with universities to improve vaccination efforts and awareness. The letter also urges the Joint Committee on Vaccination and Immunisation to expedite its review of meningitis vaccine eligibility. Club Chemistry owner Louise Jones-Roberts advocates for extending the vaccine to all under-25s.
Outbreak Details and Risk Assessment
The UK Health Security Agency reported 15 confirmed cases and 12 under investigation as of Wednesday, bringing the total to 27, up from 20 previously. Two students have died in the outbreak. Mr. Streeting warned that more cases are likely due to the seven to ten-day incubation period of meningitis B, and unrelated cases may emerge elsewhere, as the UK typically sees at least 350 cases annually. He emphasized that the risk to the general public is extremely low, noting that meningitis B spreads through prolonged close contact, such as kissing, and is not akin to COVID-19 in terms of transmission.
Vaccine Efficacy and Protection Duration
The vaccine being used, Bexsero, protects against up to 80% of meningitis B strains. Partial immunity develops about two weeks after the first dose, but full protection requires two doses spaced at least four weeks apart. Experts estimate that protection can last for years, potentially up to 36 months after the second dose. In Kent, the vaccine is being administered alongside antibiotics as an extra precaution.
Guidance for Students and Symptom Awareness
For students who have left campus, arrangements are being developed to allow vaccination through GPs. Symptoms of meningitis and sepsis include:
- High temperature and cold extremities
- Vomiting, confusion, and muscle pain
- Pale, mottled skin or a rash
- Headache, stiff neck, and sensitivity to light
- Drowsiness and seizures
The UKHSA advises anyone experiencing these symptoms to contact their GP or call NHS 111 immediately for medical assistance.
